CSS
XFOR icon

Cubist Systematic Strategies’s X4 Pharmaceuticals XFOR Stock Holding History

Cubist Systematic Strategies’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-16
Closed -$652 – 4156
2024
Q1 		$652 Sell
16
-38
-70% -$1.06K ﹤0.01% 3606
2023
Q4 		$1.35K Sell
54
-28
-34% -$681 ﹤0.01% 3466
2023
Q3 		$2.68K Buy
+82
New +$3.58K ﹤0.01% 3196
2023
Q2 		– Hold
0
– – – 3403
2022
Q3 		– Sell
-13
Closed – – 4768
2022
Q2 		$0 Sell
13
-34
-72% -$1.29K ﹤0.01% 4601
2022
Q1 		$2K Buy
+47
New +$2.69K ﹤0.01% 3517
2021
Q3 		– Sell
-438
Closed -$85K – 3203
2021
Q2 		$85K Buy
+438
New +$110K ﹤0.01% 2729

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cubist Systematic Strategies's XFOR Position: Q2 2024 in Review

Cubist Systematic Strategies sold out of X4 Pharmaceuticals (XFOR) in Q2 2024, closing a stake of 16 shares — an estimated $652 sold.

Cubist Systematic Strategies first reported a position in XFOR in Q2 2021 and held it in 6 quarters. The position peaked at $85K in Q2 2021. 98 funds tracked by Wall St. Rank hold XFOR as of Q2 2024.

  • Cubist Systematic Strategies reported no remaining X4 Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 16 X4 Pharmaceuticals shares in Q2 2024, an estimated $652.
  • Cubist Systematic Strategies first reported a position in X4 Pharmaceuticals in Q2 2021 and held it in 6 quarters.
  • Cubist Systematic Strategies's X4 Pharmaceuticals position peaked at $85K in Q2 2021.
  • 98 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2024.

Based on Cubist Systematic Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.